Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway

dc.contributor.authorWang, Luqi
dc.contributor.authorWang, Yue
dc.contributor.authorChen, Andy
dc.contributor.authorTeli, Meghana
dc.contributor.authorKondo, Rika
dc.contributor.authorJalali, Aydin
dc.contributor.authorFan, Yao
dc.contributor.authorLiu, Shengzhi
dc.contributor.authorZhao, Xinyu
dc.contributor.authorSiegel, Amanda
dc.contributor.authorMinami, Kazumasa
dc.contributor.authorAgarwal, Mangilal
dc.contributor.authorLi, Bai-Yan
dc.contributor.authorYokota, Hiroki
dc.contributor.departmentBiomedical Engineering, School of Engineering and Technologyen_US
dc.date.accessioned2021-08-09T18:29:20Z
dc.date.available2021-08-09T18:29:20Z
dc.date.issued2019-10-04
dc.description.abstractBone is a frequent site of metastasis from breast cancer, and a desirable drug could suppress tumor growth as well as metastasis-linked bone loss. Currently, no drug is able to cure breast cancer–associated bone metastasis. In this study, we focused on statins that are known to inhibit cholesterol production and act as antitumor agents. After an initial potency screening of 7 U.S. Food and Drug Administration–approved statins, we examined pitavastatin as a drug candidate for inhibiting tumor and tumor-induced bone loss. In vitro analysis revealed that pitavastatin acted as an inhibitor of tumor progression by altering stress to the endoplasmic reticulum, down-regulating peroxisome proliferator–activated receptor γ, and reducing Snail and matrix metalloproteinase 9. In bone homeostasis, it blocked osteoclast development by suppressing transcription factors c-Fos and JunB, but stimulated osteoblast mineralization by regulating bone morphogenetic protein 2 and p53. In a mouse model, pitavastatin presented a dual role in tumor inhibition in the mammary fat pad, as well as in bone protection in the osteolytic tibia. In mass spectrometry–based analysis, volatile organic compounds (VOCs) that were linked to lipid metabolism and cholesterol synthesis were elevated in mice from the tumor-grown placebo group. Notably, pitavastatin-treated mice reduced specific VOCs that are linked to lipid metabolites in the mevalonate pathway. Collectively, the results lay a foundation for further investigation of pitavastatin’s therapeutic efficacy in tumor-induced bone loss, as well as VOC-based diagnosis of tumor progression and treatment efficacy.—Wang, L., Wang, Y., Chen, A., Teli, M., Kondo, R., Jalali, A., Fan, Y., Liu, S., Zhao, X., Siegel, A., Minami, K., Agarwal, M., Li, B.-Y., Yokota, H. Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway.en_US
dc.identifier.citationWang, L., Wang, Y., Chen, A., Teli, M., Kondo, R., Jalali, A., Fan, Y., Liu, S., Zhao, X., Siegel, A., Minami, K., Agarwal, M., Li, B.-Y., & Yokota, H. (2019). Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway. The FASEB Journal, 33(12), 13710–13721. https://doi.org/10.1096/fj.201901388Ren_US
dc.identifier.issn1530-6860en_US
dc.identifier.urihttps://hdl.handle.net/1805/26398
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1096/fj.201901388Ren_US
dc.relation.journalThe FASEB Journalen_US
dc.sourcePMCen_US
dc.subjectbreast canceren_US
dc.subjectVOCen_US
dc.subjectosteoclastsen_US
dc.subjectbone metastasisen_US
dc.titlePitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathwayen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894072/en_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
fj.201901388R.pdf
Size:
2.55 MB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: